In July 2018, the court denied in largest part the defendants’ motion to dismiss this important securities class action against international pharmaceutical company, Perrigo plc. Plaintiffs allege that the company misled investors as to its revenue growth potential in order to encourage them to reject a tender offer by Mylan N.V.

Read about the case here.